Jasper Therapeutics (JSPR): Price-to-Revenue Ratio

Symbol and logo of brand Jasper Therapeutics (JSPR)

Jasper Therapeutics is actively forming strategic alliances with industry behemoths for joint research. The current P/S multiple reflects market expectations, with the mark serving as a relevant indicator. The company's financial stability relies on external infusions and grants. The development of targeted therapies for lymphomas and anemias allows for the effective distribution of risks across various clinical directions.

JSPR: Jasper Therapeutics, Inc. P/S Multiple 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for Jasper Therapeutics (JSPR)

- current price and projected stock value:
Price Chart jaspertherapeutics.com|JSPR - Price Target Chart
- stock exchange capitalization data:
Market Value Jasper Bio|JSPR - Real Price to Acquire Entire Company
- issuer book value statistics:
Accounting Value of a Share Jasper Therapeutics|JSPR - Book Capitalization|Market Value to Equity Ratio jaspertherapeutics.com|JSPR - Company Total Assets
- business debt structure and liquidity details:
Debt to Capital Jasper Therapeutics|JSPR - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio jaspertherapeutics.com|JSPR - Company Aggregate Debts|Debts to Book Value Jasper Bio|JSPR - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Jasper Therapeutics|Intermediate Liquidity Ratio jaspertherapeutics.com
- earnings and valuation multiples information:
JSPR - Net Profit|Expected Net Income Jasper Therapeutics|JSPR - P/E Multiple|Projected Price to Earnings Ratio jaspertherapeutics.com|JSPR - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Jasper Bio|JSPR - Operating profit EBITDA|Net earnings per share (EPS TTM) Jasper Therapeutics|JSPR - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months jaspertherapeutics.com|JSPR - Net earnings per share growth this year|Expected net earnings per share growth next year Jasper Therapeutics
- issuer revenue and sales details:
JSPR - Company Revenue|Company Projected Revenue Volume jaspertherapeutics.com|JSPR - P/S Multiple|Forward P/S Multiple Jasper Bio
General company analysis:JSPR - Jasper Therapeutics Inc
Mass-produced product of Jasper Therapeutics Inc

The P/S ratio compares the market value of Jasper Therapeutics (JSPR) to its annual sales volume, reflecting a premium for future growth. This metric allows investors to assess the extent to which the asset is overbought relative to the revenue generated. For a biotech brand with strong scientific authority in targeted therapy, this indicator often reflects market expectations for clinical success. By analyzing the company's P/S level, one can determine the risks of a capital drawdown should the trend reverse.

Who Jasper Therapeutics competes with

Price-to-Revenue Ratio LEGN (legendbiotech.com)|Price-to-Revenue Ratio Sana Biotechnology, Inc. SANA|Autolus Therapeutics PLC - Price-to-Revenue Ratio|ALLO: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RNAC (Selecta Biosciences Inc.)|CLLS: P/S Multiple|Price-to-Revenue Multiple cariboubio.com CRBU|TIL (Instil Bio) - P/S Multiple|Price to Sales Genenta GNTA|Price-to-Revenue Ratio Century Therapeutics (IPSC)|sentibio.com - Market Cap to Revenue Ratio|P/S Multiple ADAP (Adaptimmune Therapeutics)|CERo Therapeutics Holdings, Inc. (CERO) - Price to Sales|TCRT: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACHL (Achilles Therapeutics)|CRGX (Cargo Therapeutics) - Market Cap to Revenue|PSTX: Market Cap to Sales Volume|TSVT (2seventy bio, Inc.) - P/S Multiple|GRCL: Market Capitalization-to-Revenue Ratio